Cirrhosis is an important cause of morbidity and mortality in people with chronic liver
disease worldwide. In 2019, cirrhosis was associated with 2.4% of global deaths. Owing to …

Obesity leads to chronic, systemic inflammation and can lead to insulin resistance (IR), β-cell
dysfunction, and ultimately type 2 diabetes (T2D). This chronic inflammatory state …

Abbreviations: AASLD, American Association for the Study of Liver Diseases; AI, artificial
intelligence; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AUROC …

Background Nonalcoholic steatohepatitis (NASH) is a progressive liver disease with no
approved treatment. Resmetirom is an oral, liver-directed, thyroid hormone receptor beta …

Liver cancer epidemiology is changing due to increasing alcohol consumption, rising
prevalence of obesity, and advances in hepatitis B virus (HBV) and hepatitis C virus (HCV) …

Nonalcoholic fatty liver disease (NAFLD) and its more severe form, nonalcoholic
steatohepatitis (NASH), represent a growing worldwide epidemic and a high unmet medical …

Background Pegozafermin is a long-acting glycopegylated (pegylated with the use of site-
specific glycosyltransferases) fibroblast growth factor 21 (FGF21) analogue in development …

Non-alcoholic fatty liver disease (NAFLD) has become an epidemic, much like other non-
communicable diseases (NCDs), such as cancer, obesity, diabetes, and cardiovascular …

The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …

Background Patients with non-alcoholic steatohepatitis (NASH)-related cirrhosis are at high
risk of liver-related and all-cause morbidity and mortality. We investigated the efficacy and …